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Introduction
Use of antiplatelet agents is common in the developed world, with approximately 6-8% of people in the UK taking an antiplatelet agent [1] . Alongside the benefit of these drugs in patients with cardiovascular risk factors, is the need for protocols to manage unexpected or severe bleeding, and how to manage patients at the time of surgery. The degree of platelet dysfunction is correlated with bleeding risk [2] but stopping these agents may result in (rebound) cardiovascular morbidity [3] . Deficits of platelet function are also seen in other settings, notably cardiopulmonary bypass (CPB), where platelet dysfunction has been associated with a greater risk of postoperative bleeding [4] . Platelet dysfunction in CPB may be a result of reduced availability of platelet agonists rather than intrinsic platelet defects [5] and CPB has been reported to increase platelet activation markers such as thromboglobulin, platelet factor 4 and P-selectin [6] .
When rapid reversal of antiplatelet therapy is necessary, many guidelines have recommended transfusion of two to three adult doses of platelets [7] [8] [9] but acknowledge the lack of evidence to support the strength of this recommendation [10, 11] . In addition, the optimal use of platelet transfusions has become less clear following the publication of the PATCH trial. This randomized trial of platelet transfusion vs. standard care in intracranial hemorrhage [12] reported that platelet transfusion was of no benefit in reducing bleeding and led to a poorer outcome with increased mortality and poorer function. Although the results of this trial may not be applicable in all settings where there is platelet dysfunction, they raise important questions about the risk to benefit ratio of platelet transfusions.
Desmopressin (also known as DDAVP or 1-deamino-8-D-arginine vasopressin) has been used for the treatment of congenital bleeding disorders for almost four decades. It acts by increasing plasma von Willebrand factor, factor VIII and intracellular platelet calcium/ sodium ion concentrations, and by increasing formation of procoagulant platelets and platelet adhesion to collagen under flow [13] [14] [15] . Desmopressin is also recommended in a number of guidelines for treatment of bleeding in patients with platelet dysfunction or on antiplatelet agents [9, [16] [17] [18] [19] , but there has been no formal/ systematic review of the size of the benefit and the risks of desmopressin in the context of antiplatelet therapy. Desmopressin use is associated with side-effects including hypotension, hyponatremia, facial flushing and a theoretical risk of thrombotic events.
The aim of this review was to examine the evidence for perioperative administration of desmopressin to reduce bleeding risk and transfusion requirements for people with platelet dysfunction as a result of antiplatelet drug therapy or CPB.
Methods
This systematic review followed the methods in the prospectively registered update of a Cochrane review [20] . Methodology was consistent with the definitions from the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement [21] .
Eligibility criteria
We only included randomized controlled trials (RCTs) of participants undergoing any type of elective or emergency surgery. Participants were taking antiplatelet agents (cyclo-oxygenase-1 inhibitors, phosphodiesterase inhibitors or P2Y 12 inhibitors) or had established platelet dysfunction as measured by recognized tests, including platelet function analyzer (PFA). Trials were included if at least 80% of participants had evidence of platelet dysfunction or were taking antiplatelet agents, or if it was possible to extract data on a subgroup of participants with platelet dysfunction. Trials were eligible for inclusion if their intervention was intravenous or subcutaneous desmopressin. Comparators were placebo or standard care. 
Primary outcome

Data extraction
Trial selection Two independent review authors initially used an online systematic review management tool (DistillerSR; https://v2.systematic-review.ca) to screen all electronically-derived citations and abstracts of papers identified by the review search strategy for relevance. Studies that were clearly irrelevant were excluded at this stage.
The full texts of all potentially relevant trials were then formally assessed for eligibility against the criteria outlined above by two independent review authors. All disagreements were resolved by discussion with the other authors. Further information was sought from study authors when an article contained insufficient data to make a decision about eligibility. A study eligibility form was designed using an online systematic review management tool (Covidence; https://www.covide nce.org/) for trials of desmopressin to help in the assessment of relevance. The reasons why potentially relevant studies failed to meet the eligibility criteria were recorded.
Risk of bias assessment and grading the quality of evidence
We assessed the risk of bias using the methods outlined in the Cochrane Collaboration Handbook for Systematic Reviews of Interventions [22] . Risk of bias was assessed as high, low or unclear for each of: selection bias, performance bias, detection bias, attrition bias, reporting bias and other sources of bias. We did not assess publication bias, as we identified fewer than 10 trials contributing data towards the primary outcome.
We assessed the quality of evidence for each outcome according to Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria. GRADE quality was classified as very low, low, moderate or high [23] .
Data synthesis and analysis
All statistical analyses were performed using Review Manager 5.3 (http://tech.cochrane.org/revman) and presented as forest plots. When meta-analysis was feasible, we used the random-effect model and the Mantel-Haenszel method for pooling the data. Meta-analysis was undertaken where data were sufficient. We reported risk ratios (RRs) for dichotomous outcomes, with 95% confidence intervals (CIs). The Peto odds ratio (pOR) was used for outcomes with low event rates. Mean differences (MDs) with 95% CIs were calculated for continuous outcomes. Where appropriate we calculated number needed to treat, or number needed to harm.
Assessment of heterogeneity Statistical heterogeneity of treatment effects between trials was assessed using a chisquared test with a significance level at P < 0.1. The I 2 statistic was used to quantify the percentage of variability that was due to heterogeneity (we defined heterogeneity of between 50% and 80% as moderate and > 80% as substantial).
Sensitivity and subgroup analysis Sensitivity analyses were performed by assessing results using only trials considered to be at low risk of bias from blinding of study outcome assessors. Trials where platelet dysfunction was due to antiplatelet agents or other causes were included in separate subgroups. We planned to examine different types of surgery in separate subgroups but all trials identified in this review were in the same setting (cardiac surgery). We examined statistical heterogeneity between subgroups using the I 2 statistic.
Unpublished data We had access to individual patient data from one trial [24] and data on the subgroup of patients who were taking antiplatelet agents was extracted for incorporation into a meta-analysis.
Results
Search results
The search strategy identified 3474 references, which were reduced to 2322 after exclusion of duplicates (Fig. 1) ; 2208 references were excluded as they were clearly not relevant to the review and the full texts of the remaining 114 references were analyzed in full. One hundred and four references were excluded for the following reasons: five, review articles; 14, not randomized controlled trials; 61, wrong participant group; five, incorrect intervention; 19, secondary citations of excluded trials. Ten trials (596 participants) were included in the qualitative synthesis and nine trials were included in the quantitative synthesis.
Trial characteristics
Although all surgical procedures regardless of specialty were potentially eligible, all 10 relevant trials were in the setting of cardiac surgery. Six trials included participants undergoing coronary artery bypass grafting (CABG) [25] [26] [27] [28] [29] [30] , one trial included aortic valve replacements [31] and three trials included a combination of CABG and valve replacements [24, 32, 33] . Nine trials included only elective surgery [24] [25] [26] [28] [29] [30] [31] [32] [33] and one trial included only emergency cases [27] . Platelet dysfunction was a result of antiplatelet agents in six trials: single-agent aspirin in four trials [25, 26, 29, 30] , dual antiplatelet therapy in one trial [27] and a combination of single-agent aspirin and dual antiplatelet therapy in one trial [24] . Platelet dysfunction was a result of CPB in four trials [28, [31] [32] [33] . One trial was published in abstract form only [27] . Desmopressin was administered as a single intravenous dose of 0.3 lg kg À1 in eight trials [24] [25] [26] [27] [28] [29] 31, 32] , 0.4 lg kg À1 in one trial [33] and 10 lg m À2 body surface area in one trial [30] . One trial was a four-arm trial comparing desmopressin 0.3 lg kg
À1
, standard care, a combination of desmopressin 0.3 lg kg À1 with tranexamic acid, and tranexamic acid as a single agent [27] . Desmopressin was given preoperatively in one trial [31] , intra-operatively but after CPB in five trials [25, 26, [28] [29] [30] , postoperatively in three trials [27, 32, 33] , and either intra-operatively or postoperatively in one trial [24] . In nine trials desmopressin was administered prophylactically to prevent bleeding [25] [26] [27] [28] [29] [30] [31] [32] [33] and in one trial it was administered to treat bleeding [24] . Nine trials compared desmopressin with a matching 0.9% saline placebo [24] [25] [26] [28] [29] [30] [31] [32] [33] and one trial was an open-label trial comparing desmopressin with standard care or tranexamic acid [27] . Trials were published between 1992 and 2016. Characteristics of included studies are reported in Table 1 .
Effects on outcomes
Total volume of allogeneic red cells transfused This outcome was reported in seven trials [24] [25] [26] 28, [31] [32] [33] . One trial reported this in a way that could not be included in meta-analysis and is reported separately in Table 2 [28] . Overall, participants treated with desmopressin required fewer units of red cells than those treated with placebo (MD, À0.65 units; 95% CI, À1.16 to À0.13; I 2 = 36%; 388 participants; six trials; Fig. 2A ) [24] [25] [26] [31] [32] [33] . The sensitivity analyses supported the results of the main analysis (MD, À0.82 units; 95% CI, À1.29 to À0.34; I 2 = 14%; 296 participants; four trials) [24, 26, 31, 33] . The GRADE quality of evidence was judged to be low (Table 3) .
The effect was similar for the subgroup of participants with platelet dysfunction as a result of antiplatelet agents (MD, À0.90 units; 95% CI, À1.62 to À0.18; I 2 = 36%; 152 participants; three trials) [24] [25] [26] and with platelet dysfunction as a result of CPB (MD, À0.43 units; 95% CI, À1.22 to 0.37; I 2 = 56%; 236 participants; three trials) [31] [32] [33] . There was no evidence of heterogeneity between the subgroups: I 2 = 0%.
Total number of participants receiving an allogeneic red cell transfusion This outcome was reported in six trials [24] [25] [26] [28] [29] [30] . One trial was not included in the analysis because every participant in both arms was transfused [26] . No difference was found in the risk of allogeneic red cell transfusion for participants treated with desmopressin compared with placebo (RR, 0.83; 95% CI, 0.66-1.04; I 2 = 14%; 258 participants; five trials; Fig. 2B ) [24, 25, [28] [29] [30] . The sensitivity analyses supported the results of the main analysis (RR, 0.91; 95% CI, 0.62-1.32; I 2 = 43%; 185 participants; three trials) [24, 28, 30] . The GRADE quality of evidence was judged to be low (Table 3) .
The effect was similar for the subgroup of participants with platelet dysfunction as a result of antiplatelet agents (RR, 0.82; 95% CI, 0.61-1.10; I 2 = 32%; 229 participants; four trials) [24, 25, 29, 30] , but was smaller for those with platelet dysfunction as a result of CPB (RR, 0.92; 95% CI, 0.58-1.46; 29 participants; one trial) [28] . There was no evidence of heterogeneity between the subgroups:
Total volume of blood loss This outcome was reported in all trials. Three trials reported this in a way that could not be included in a meta-analysis and are reported separately in Table 2 [25, 27, 32] . Overall, participants treated with desmopressin lost less blood than those treated with placebo (MD, À253.93 mL; 95% CI, À408.01 to À99.85 mL; I 2 = 75%; 422 participants; seven trials; Fig. 3A ) [24, 26, [28] [29] [30] [31] 33] . The sensitivity analyses supported the © 2016 International Society on Thrombosis and Haemostasis results of the main analysis (MD, À370.00 mL; 95% CI, À556.65 to À183.35; I 2 = 63%; 276 participants; five trials) [26, 28, 30, 31, 33] . The GRADE quality of evidence was judged to be low (Table 3) .
The effect was similar for the subgroup of participants with platelet dysfunction as a result of antiplatelet agents (MD, À249.90 mL; 95% CI, À535.26 to 35.46 mL; I 2 = 78%; 249 participants; four trials) [24, 26, 29, 30] and with platelet dysfunction as a result of CPB (MD, À295.73 mL; 95% CI, À484.20 to À107.26 mL; I 2 = 61%; 173 participants; three trials) [28, 31, 33] . There was no evidence of heterogeneity between the subgroups: I 2 = 0%. Re-operation because of bleeding This outcome was reported in six trials [24, 28, 29, [31] [32] [33] . The risk of re-operation because of bleeding was lower for participants treated with desmopressin compared with participants treated with placebo (pOR, 0.39; 95% CI, 0.18-0.84; I 2 = 0%; 413 participants; six trials; Fig. 3B ) [24, 26, [28] [29] [30] [31] 33] . The number needed to treat to prevent one patient requiring re-operation because of bleeding was 17. The sensitivity analyses CI, confidence interval; MD, mean difference; pOR, Peto odds ratio; RCT, randomized controlled trial; RR, risk ratio. *Downgraded one point because of risk of bias from blinding of outcome assessors and incomplete outcome data. †Downgraded one point for inconsistency due to variation in baseline level of transfusion and blood loss. ‡Downgraded two points for imprecision, as confidence intervals include clinically significant benefit and clinically significant harm with low background event rate. §Downgraded one point for imprecision.
supported the results of the main analysis (pOR, 0.48; 95% CI, 0.17-1.34; I 2 = 37%,; 292 participants; four trials) [24, 28, 31, 33] . The GRADE quality of evidence was judged to be moderate (Table 3) .
There was moderate evidence of heterogeneity between the subgroups: I 2 = 52.5%. The effect was smaller for the subgroup of participants with platelet dysfunction as a result of antiplatelet agents (pOR, 0.77; 95% CI, 0.23-2.54; 148 participants; two trials) [24, 29] than for those with platelet dysfunction as a result of CPB (pOR, 0.24; 95% CI, 0.09-0.66; I 2 = 0%; 265 participants; four trials) [28, [31] [32] [33] .
Adverse events All-cause mortality This outcome was reported in seven trials [24, 26, [28] [29] [30] [31] 33] . Four trials reported no deaths in either arm [28] [29] [30] [31] . No difference was found in the risk of all-cause mortality for participants treated with desmopressin compared with placebo (pOR, 0.72; 95% CI, 0.12-4.22; I 2 = 24%; 422 participants; seven trials) [24, 26, [28] [29] [30] [31] 33] . The baseline risk of mortality was less than 1%, limiting interpretation of these results due to imprecision. The GRADE quality of evidence was judged to be very low (Table 3) .
Thrombotic events This outcome was reported in seven trials [24, 26, [28] [29] [30] [31] 33] . No difference was found in the risk of a thrombotic event for participants treated with desmopressin compared with placebo (pOR, 1.58; 95% CI, 0.60-4.17; I 2 = 0%; 422 participants; seven trials) [24, 26, [28] [29] [30] [31] 33] . The event rate was low for individual causes of thrombotic events, with no overall difference in the incidence of any type of thrombotic event: myocardial infarction (pOR, 2.72; 95% CI, 0.60-12.37; I 2 = 0%; 277 participants; five trials) [24, 26, 28, 29, 31] , ischemic stroke (pOR, 1.21; 95% CI, 0.07-20.17; I 2 = 0%; 157 participants; three trials) [24, 26, 30] or venous thromboembolism (pOR, 0.56; 95% CI, 0.06-5.50; 248 participants; four trials) [24, 26, 29, 31] . The GRADE quality of evidence was judged to be low (Table 3) .
Clinically significant hypotension This outcome was reported in five trials [24, 25, 28, 29, 33] . No events occurred in either arm of two trials [28, 33] . There was an increase in the risk of clinically significant hypotension for participants treated with desmopressin compared with placebo (pOR, 9.78; 95% CI, 2.48-38.58; I 2 = 0%; 315 participants; five trials) [24, 25, 28, 29, 33] . The number needed to treat for one episode of clinically significant hypotension was 17. The GRADE quality of evidence was judged to be low (Table 3) .
Other adverse events Other adverse events, including hyponatremia, seizures, chest tightness, hypertension, abdominal pain, headache, nausea and allergic reactions, were not reported in the included trials. Risk of bias Key potential sources of bias for these trials were blinding of outcome assessors and incomplete outcome data. In six trials we considered blinding of outcome assessors to be at low risk of bias because the person preparing the desmopressin or matching placebo was not otherwise involved in the trial [24] [25] [26] 29, 31, 33] . One trial was open label and was considered to be at high risk of bias [27] . Insufficient details were reported in the manuscripts of the remaining trials for an assessment of bias to be made [28, 30, 32] .
A key problem for several trials was whether to include individuals with exsanguinating or large-volume hemorrhages after randomization. We considered five trials to be at low risk of bias because all participants were included in the final analysis [24, 26, 28, 30, 33] . Three trials were considered to be at high risk of bias because at least one individual with a large-volume hemorrhage was excluded from the final results [25, 29, 32] . With such small trials, such an individual could significantly alter the results for the continuous outcomes: volume of allogeneic red cells transfused and total blood loss. The remaining trials did not report sufficient information for an assessment of bias to be made [27, 31] .
GRADE quality of the evidence Overall the GRADE quality of evidence was very low to moderate, suggesting considerable uncertainty over the results and that further clinical trial information may significantly alter the results (Table 3 ). The quality assessment of all outcomes was downgraded one point for risk of bias. Volume of red cells transfused, risk of red cell transfusion and blood loss were downgraded one point for inconsistency, as there were significant variations in baseline blood loss and transfusion requirements between studies. All-cause mortality was downgraded two points for imprecision, as the event rate was very low and consequently the confidence interval included both significant benefit and significant harm. Risk of a thrombotic event and clinically significant hypotension were downgraded one point for imprecision.
Discussion
Antiplatelet agent use is rising in many countries and yet the treatment options to manage major bleeding or cover for urgent surgery are limited. This is particularly problematic following the recent publication of the PATCH trial [12] . Platelet dysfunction is also expected as a consequence of CPB, when again there is uncertainty about the role of platelet transfusions. This meta-analysis identified 10 randomized trials with 596 participants where the effects of desmopressin were assessed. All trials were in the setting of cardiac surgery and platelet dysfunction was caused by antiplatelet agents in six trials and CPB in four trials. Desmopressin may be an attractive agent for use in this patient population, given its ease of administration, mechanism of action and low cost.
Desmopressin administration resulted in transfusion of fewer units of red cells (equivalent to a 25% reduction compared with control), less blood loss (equivalent to a 23% reduction compared with control) and a lower risk of requiring a re-operation because of bleeding. No difference was found in the risk of receiving an allogeneic red cell transfusion. Similar results were found for the subgroups with platelet dysfunction as a result of antiplatelet agents and CPB, with little evidence of statistical heterogeneity between subgroups. For the outcome of re-operation because of bleeding, the odds of returning to theatre with bleeding were lower in the subgroup with platelet dysfunction caused by CPB than in those taking antiplatelet agents.
Event rates were generally low for adverse events. There were no overall differences reported in the risk of all-cause mortality or thrombotic events (myocardial infarction, stroke and venous thromboembolism) for patients treated with desmopressin. Larger trials are required to confirm or refute any increased thrombotic risk, particularly in patients with ischemic heart disease. Patients treated with desmopressin had an increased risk of clinically significant hypotension, which is consistent with the results of other reviews [20, 34] . This adverse event may be more common when desmopressin is administered rapidly [35] , but it is unclear whether transient hypotension has more severe outcomes, although no other imbalances of risks were seen across all trials. Other adverse events such as facial flushing, hyponatremia and seizures were not reported.
In summary, the results suggested that desmopressin might have some effect in reducing blood loss and red cell transfusion requirements for patients with platelet dysfunction who undergo cardiac surgery. The efficacy of desmopressin for the treatment of patients taking antiplatelet agents appears to be greater than that for treatment of unselected patients [20, 34] .
Limitations of this review
All of the trials were in the setting of cardiac surgery. All trials were small and five of the 10 trials were undertaken more than 20 years ago when different standards of practice in cardiac surgery existed. Patients undergoing emergency surgery were included in only one out of 10 trials and desmopressin was used for treatment (rather than prophylaxis) of bleeding in only one of 10 trials. The majority of patients taking antiplatelet agents were taking single-agent aspirin, with relatively few patients taking dual antiplatelet therapy or other antiplatelet agents. There was heterogeneity in the nature and timing of desmopressin administration in the trial protocols for the included trials. Many trials were considered to be at risk of bias because of insufficient information on blinding of study outcome assessors and incomplete outcome data. Given these limitations and the low-quality GRADE levels of evidence, the findings highlight the need for caution in extrapolating the research to areas outside cardiac surgery but also the opportunities for further clinical research. It is unclear whether desmopressin is more or less effective than tranexamic acid, or whether it may be used in addition to tranexamic acid or other antifibrinolytic agents.
Meta-analyses of the total volume of allogeneic red cells transfused and total blood loss were limited because of inconsistency in baseline levels of red cell transfusion and blood loss. The findings of our review were also limited by data published in a format that could not be incorporated into meta-analysis, which showed inconsistent results. There were few numbers of events for all-cause mortality, thrombotic events and clinically significant hypotension, which limited interpretation of the results.
Conclusion
Overall this review provides some evidence for the use of desmopressin to reduce bleeding and transfusion requirements for people taking antiplatelet agents undergoing surgery. However, there remains uncertainty regarding the size of the benefit and the risks of cardiac surgery, including thrombotic events. Significant research gaps exist outside cardiac surgery (including in acute blood loss), and regarding the use of desmopressin for treating antiplatelet agents other than aspirin and the role of desmopressin in conjunction with an antifibrinolytic agent. To a degree, these findings reproduce the program of clinical research for use of tranexamic acid, which is still ongoing. The biological rationale and findings of this review support a need for further research into the use of desmopressin in the setting of platelet dysfunction and management of bleeding or perioperative protocols in patients taking antiplatelet agents. one of the studies included in this review. There was no specific funding for this meta-analysis. The other authors state that they have no conflict of interest.
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